Press release: Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology
07 janv. 2025 01h00 HE
|
Sequana Medical NV
Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology alfapump® system is...
Press release: Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST
06 janv. 2025 01h00 HE
|
Sequana Medical NV
Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST Webinar to discuss US commercial roll-out following FDA...
Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
23 déc. 2024 01h00 HE
|
Sequana Medical NV
Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis alfapump® is the first US approved active implantable medical device...
Press Release: Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing
20 déc. 2024 14h00 HE
|
Sequana Medical NV
Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing Ghent, Belgium – 20 December 2024 – Sequana Medical NV (Euronext Brussels:...
Press Release: Sequana Medical announces decision of major shareholders to invest in Second Tranche of Convertible Bridge Loan
06 déc. 2024 01h00 HE
|
Sequana Medical NV
SEQUANA MEDICAL ANNOUNCES DECISION OF MAJOR SHAREHOLDERS TO INVEST IN SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium, 6 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the...
Press Release: Sequana Medical announces update on second tranche of convertible bridge loan
02 déc. 2024 02h00 HE
|
Sequana Medical NV
SEQUANA MEDICAL ANNOUNCES UPDATE ON SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium – 2 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a...
Press Release: Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical’s Direct Sodium Removal Heart Failure Program and Board Composition Update
27 nov. 2024 01h00 HE
|
Sequana Medical NV
Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical’s Direct Sodium Removal Heart Failure Program and Board Composition Update More efficient sodium and fluid removal,...
Press Release: Transparency Notification from Shareholders
26 nov. 2024 01h00 HE
|
Sequana Medical NV
Transparency Notification from Shareholders Ghent, Belgium – 26 November 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid...
Press Release: Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024
20 nov. 2024 01h00 HE
|
Sequana Medical NV
Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024 Ghent, Belgium – 20 November 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or...
Press Release: Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025
18 nov. 2024 01h00 HE
|
Sequana Medical NV
Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025 alfapump was very effective in...